Rznomics Wins Most Promising Gene Therapy Pipeline Award at International Events for the second consecutive year

ACGTEA  of  CGTWA 2023

Rznomics announced on the 18th that it has won the Most Promising Pipeline Award in the gene therapy category at the ‘Asia Pacific Cell & Gene Therapy Excellence Awards (ACGTEA)’ at the ‘Cell & Gene Therapy World Asia 2023 (CGTWA 2023)’ held in Singapore. It has been awarded for the second consecutive year since 2022.

CGTWA is an event that shares representative technologies of cell and gene therapy products of pharmaceutical and biotechnology companies based in the Asia-Pacific region.
Through this award ceremony, Rznomics introduced the status of trans-splicing ribozyme-based gene therapy platform technology and circular RNA technology. The company's circular RNA technology has been applied for international patents(PCT) and patents in major countries including the United States, after securing pipelines and domestic original patent rights.

Last year, Rznomics received clinical approval for liver cancer treatment from the Korean Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA). Phase 1 clinical trials of "RZ-001" are being conducted at five hospitals in Korea. In the future, phase 2 clinical trials will be conducted simultaneously in Korea and the United States.

In addition, it received clinical approval from the Korean Ministry of Food and Drug Safety and FDA in May this year for glioblastoma treatment. It plans to conduct clinical trials within this year. Rznomics also plans to apply for clinical trials early next year for autosomal dominant retinitis pigmentosa, which currently has no treatment at all.
Seong-wook Lee, CEO of Rznomics, said, "The award for the second consecutive year will be an opportunity to recognize and promote Rznomics' technology more widely. We will do our best to implement Rznomics' technology as an innovative treatment that can solve the unmet demand for rare and incurable diseases."